Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011–2017: A Retrospective Cohort Study (Korean TB-POST)-Reference-Cited by-同舟云学术

Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011–2017: A Retrospective Cohort Study (Korean TB-POST)

Published:2023 Issue:5 Volume:38 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Choi Hongjo¹^ORCID,Mok Jeongha²^ORCID,Kang Young Ae³^ORCID,Jeong Dawoon⁴^ORCID,Kang Hee-Yeon⁵^ORCID,Kim Hee Jin⁶^ORCID,Kim Hee-Sun⁷^ORCID,Jeon Doosoo⁸^ORCID

Affiliation:

1. Department of Preventive Medicine, Konyang University College of Medicine, Daejeon, Korea.

2. Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

3. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

4. Research and Development Center, the Korean Institute of Tuberculosis, Korean National Tuberculosis Association, Cheongju, Korea.

5. Department of Health Policy and Management, Seoul National University College of Medicine, Seoul, Korea.

6. Central Training Institute, Korean National Tuberculosis Association, Seoul, Korea.

7. Department of Health Policy Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea.

8. Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.

Funder

Ministry of Health and Welfare

Korea Health Industry Development Institute

Korean National Tuberculosis Association

Publisher

XMLink

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2023.38.e33

Reference30 articles.

1. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis

2. Korea Disease Control and Prevention Agency. Annual report on the notified tuberculosis patients in Korea 2021. Updated 2022. Accessed June 1, 2022. https://www.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=1&pblctDtaSn=2598

3. Multidrug-resistant tuberculosis over 20 years at a referral hospital in South Korea: trends and outcomes

4. Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes

5. Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Comparison of Pre- and Post-Public–Private Mix Periods

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea;The Korean Journal of Internal Medicine;2024-07-01

2. Epidemiological characteristics and diagnosis and treatment effect of rifampicin-resistant pulmonary tuberculosis (RR-PTB) in Guizhou province;2024-06-12

3. Clinical course of respiratory tuberculosis relapses in the Kazakh population depending on HLA-DRB1 gene alleles;VirusDisease;2024-06

4. Epidemiology of first- and second-line drugs-resistant pulmonary tuberculosis in Iran: Systematic review and meta-analysis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-05

5. Multivariate regression analysis affecting successful treatment of pulmonary tuberculosis patients in western China: a retrospective study in a high-incidence area;2024-04-16